105 related articles for article (PubMed ID: 6941850)
1. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
Harris AL
Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
[No Abstract] [Full Text] [Related]
2. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
Ho DH; Carter CJ; Brown NS; Hester J; McCredie K; Benjamin RS; Freireich EJ; Bodey GP
Cancer Res; 1980 Jul; 40(7):2444-6. PubMed ID: 6248205
[No Abstract] [Full Text] [Related]
3. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
4. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
Harris AL; Grahame-Smith DG; Potter CG; Bunch C
Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
[TBL] [Abstract][Full Text] [Related]
5. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.
Chou TC; Arlin Z; Clarkson BD; Phillips FS
Cancer Res; 1977 Oct; 37(10):3561-70. PubMed ID: 332337
[No Abstract] [Full Text] [Related]
7. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
Bhalla K; Birkhofer M; Arlin Z; Grant S; Lutzky J; Safah H; Graham G
Exp Hematol; 1991 Aug; 19(7):669-73. PubMed ID: 1893953
[TBL] [Abstract][Full Text] [Related]
8. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
Lauzon GJ; Paran JH; Paterson AR
Cancer Res; 1978 Jun; 38(6):1723-9. PubMed ID: 274174
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
Riva CM; Rustum YM; Preisler HD
Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
[No Abstract] [Full Text] [Related]
10. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
Lauzon GJ; Paterson AR; Belch AW
Cancer Res; 1978 Jun; 38(6):1730-3. PubMed ID: 274175
[TBL] [Abstract][Full Text] [Related]
11. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
13. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Grant S; Rauscher F; Cadman E
Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007
[TBL] [Abstract][Full Text] [Related]
15. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
16. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
Spriggs D; Robbins G; Ohno Y; Kufe D
Cancer Res; 1987 Dec; 47(24 Pt 1):6532-6. PubMed ID: 3479246
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
18. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
Karp JE; Burke PJ
Cancer Res; 1976 Oct; 36(10):3600-3. PubMed ID: 1066183
[TBL] [Abstract][Full Text] [Related]
20. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.
Rustum YM; Preisler HD
Cancer Res; 1979 Jan; 39(1):42-9. PubMed ID: 282940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
